Diet Intervention for Crohn's Disease Patient
- Conditions
- Crohn Disease
- Interventions
- Other: CD LFDBehavioral: Diet CounselingBehavioral: Dyadic Psychological Support (DPS)
- Registration Number
- NCT04213729
- Lead Sponsor
- University of Miami
- Brief Summary
The purpose of this study is to determine the effectiveness of a low-fat, high fiber diet (LFD) containing a minimal proportion of fat to improve gastrointestinal symptoms, quality of life and signs of inflammation in blood and stool.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Experimental CD Low Fat Diet (LFD) Group CD LFD Participants will be provided catered LFD meals for 8 consecutive weeks consisting of daily breakfast, lunch, dinner and snacks. Crohn's Disease (CD) Control Group Diet Counseling Participants will receive only the one time standard of care in-clinic diet counseling at visit 1. Experimental CD LFD + DPS Group CD LFD Participants and one family member that lives with them will be provided catered LFD meals for 8 consecutive weeks consisting of daily breakfast, lunch, dinner and snacks. In addition, the participant and their family member will receive 12 consecutive weeks of Dyadic Psychological Support (DPS). Experimental CD LFD + DPS Group Dyadic Psychological Support (DPS) Participants and one family member that lives with them will be provided catered LFD meals for 8 consecutive weeks consisting of daily breakfast, lunch, dinner and snacks. In addition, the participant and their family member will receive 12 consecutive weeks of Dyadic Psychological Support (DPS).
- Primary Outcome Measures
Name Time Method Rate of adherence to fat intake Week 36 Adherence to fat intake is measured by the web-based Automated Self-Administered 24-hour diet recall (ASA24).
Change in fat intake Baseline, 8 weeks Change in daily fat intake calculated through patient reported diet diary app Nutrihand.
- Secondary Outcome Measures
Name Time Method Change in clinical symptoms as assessed by Patient Reported Outcomes (PRO2). Baseline, Week 8 PRO2 is the sum of the average daily stool frequency and abdominal pain. A weighted total PRO2 score of less than 75 is an indication of remission.
Change in quality of life (QoL) as assessed by the Short Inflammation Bowel Disease Questionnaire (sIBDQ). Baseline, Week 8 sIBDQ is a 10-item shortened version of the original IBDQ assessing QOL with total scores ranging from 1 to 7 with a higher score indicating a better QOL.
Change in clinical symptoms as assessed by the Short Crohn's Disease Activity Index (sCDAI). Baseline, Week 8 sCDAI is the sum of the average daily stool frequency, general well-being and abdominal pain. A weighted total sCDAI score of less than 150 indicates remission, 150-219 indicates mild activity, 220-450 indicates moderate activity and \> 450 indicates severe activity.
Change in clinical symptoms as assessed by the Harvey Bradshaw Index (HBI) Baseline, Week 8 HBI is a 5-item questionnaire. An HBI score of \<5 indicates remission, 5-7 indicates mild disease, 8-16 indicates moderate disease and \>16 indicates severe disease.
Change in the expression of cytokine high-sensitivity C-reactive protein (hsCRP). Baseline, Week 8 Change in the expression of cytokine high-sensitivity C-reactive protein (hsCRP) evaluated in mg/L.
Change in quality of life (QoL) as assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS-29). Baseline, Week 8 The PROMIS-29, a generic health-related quality of life survey, assesses each of the 7 PROMIS domains with 4 questions. The questions are ranked on a 5-point Likert Scale. There is also one 11-point rating scale for pain intensity. A score of 50 represents the mean or average of the reference population. A score of 60 means that the person is one standard deviation above the reference population (standard deviation = 10).
Change in the expression of Serum Amyloid A (SAA). Baseline, Week 8 Change in the expression of SAA evaluated in pg/mL.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
University of Miami
🇺🇸Miami, Florida, United States